AR082799A1 - Derivados de quinolina y quinoxalina como inhibidores de quinasa - Google Patents
Derivados de quinolina y quinoxalina como inhibidores de quinasaInfo
- Publication number
- AR082799A1 AR082799A1 ARP110103154A ARP110103154A AR082799A1 AR 082799 A1 AR082799 A1 AR 082799A1 AR P110103154 A ARP110103154 A AR P110103154A AR P110103154 A ARP110103154 A AR P110103154A AR 082799 A1 AR082799 A1 AR 082799A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- alkylaminocarbonyl
- alkoxy
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Que son inhibidores selectivos de enzimas de quinasa PI3, son en consecuencia beneficiosos en medicina, por ejemplo en el tratamiento de afecciones inflamatorias, autoinmunes, cardiovasculares, neurodegenerativas, metabólicas, oncológicas, nociceptivas u oftálmicas.Reivindicación 1: Un compuesto de fórmula (1) o uno de sus N-óxidos, o una de sus sales o solvatos aceptables desde el punto de vista farmacéutico caracterizado porque U representa -CF3, -CHF2 o -CH2F; Q representa oxígeno, azufre, N-R4 o un enlace covalente; Z representa un resto heteroarilo bicíclico sustituido en forma opcional que consiste en dos anillos aromáticos de seis miembros fusionados, el resto heteroarilo Z que contiene por lo menos un átomo de nitrógeno y está relacionado al resto de la molécula a través de un átomo de carbono; M representa arilo o heteroarilo, cualquiera de cuyos grupos puede estar sustituido en forma opcional por uno o más sustituyentes; W representa C-R5 o N; R1, R2 y R3 representan en forma independiente hidrógeno, halógeno, ciano, nitro, alquil trifluorometilo C1-6, cicloalquil C3-7-alquilo C1-6, heterocicloalquil C3-7-alquilo C1-6, arilalquilo C1-6, heteroarilalquilo C1-6, hidroxi, alcoxi C1-6, difluorometoxi, trifluorometoxi, alquiltio C1-6, alquilsulfinilo C1-6, alquilsulfonilo C1-6, amino, alquilamino C1-6, dialquilamino C1-6, alquilcarbonilamino C2-6, alcoxicarbonilamino C2-6, alquilsulfonilamino C1-6, formilo, alquilcarbonilo C2-6, carboxi, alcoxicarbonilo C2-6, aminocarbonilo, alquilaminocarbonilo C1-6, di-alquilaminocarbonilo C1-6, aminosulfonilo, alquilaminosulfonilo C1-6 o di-alquilaminosulfonilo C1-6; R4 representa hidrógeno o alquilo C1-6; y R5 representa hidrógeno, halógeno, alquilo C1-6 o alcoxi C1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1014963.1A GB201014963D0 (en) | 2010-09-08 | 2010-09-08 | Therapeutic agents |
| GBGB1101128.5A GB201101128D0 (en) | 2011-01-21 | 2011-01-21 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082799A1 true AR082799A1 (es) | 2013-01-09 |
Family
ID=45810169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103154A AR082799A1 (es) | 2010-09-08 | 2011-08-30 | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9029392B2 (es) |
| EP (1) | EP2614061B1 (es) |
| JP (1) | JP5820882B2 (es) |
| KR (1) | KR101880280B1 (es) |
| CN (1) | CN103153996B (es) |
| AR (1) | AR082799A1 (es) |
| AU (1) | AU2011300521B2 (es) |
| BR (1) | BR112013004750B1 (es) |
| CA (1) | CA2808959C (es) |
| CL (1) | CL2013000603A1 (es) |
| CO (1) | CO6680717A2 (es) |
| CY (1) | CY1116734T1 (es) |
| DK (1) | DK2614061T3 (es) |
| EA (1) | EA024162B1 (es) |
| ES (1) | ES2544289T3 (es) |
| HK (1) | HK1181754A1 (es) |
| HR (1) | HRP20150868T1 (es) |
| HU (1) | HUE025223T2 (es) |
| IL (1) | IL224841A (es) |
| MA (1) | MA34600B1 (es) |
| ME (1) | ME02203B (es) |
| MX (1) | MX2013002529A (es) |
| MY (1) | MY162396A (es) |
| NZ (1) | NZ607966A (es) |
| PL (1) | PL2614061T3 (es) |
| PT (1) | PT2614061E (es) |
| RS (1) | RS54202B1 (es) |
| SG (1) | SG187924A1 (es) |
| SI (1) | SI2614061T1 (es) |
| SM (1) | SMT201500195B (es) |
| TW (1) | TWI510489B (es) |
| WO (1) | WO2012032334A1 (es) |
| ZA (1) | ZA201301751B (es) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| KR101897881B1 (ko) | 2008-01-04 | 2018-09-12 | 인텔리카인, 엘엘씨 | 특정 화학 물질, 조성물 및 방법 |
| JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
| CN103002738A (zh) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | 用于激酶调节的化学化合物、组合物和方法 |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
| WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| UA115767C2 (uk) | 2011-01-10 | 2017-12-26 | Інфініті Фармасьютікалз, Інк. | Способи отримання ізохінолінонів і тверді форми ізохінолінонів |
| US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| AU2012284091B2 (en) | 2011-07-19 | 2015-11-12 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| HUE042374T2 (hu) | 2012-06-13 | 2019-06-28 | Incyte Holdings Corp | Szubsztituált triciklusos vegyületek mint FGFR inhibitorok |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
| TWI657085B (zh) | 2013-10-04 | 2019-04-21 | 英菲尼提製藥股份有限公司 | 雜環化合物及其用途 |
| US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CN104744435B (zh) * | 2013-12-25 | 2017-03-01 | 上海医药工业研究院 | 喹啉类化合物、其盐、其中间体、制备方法及应用 |
| JP6701088B2 (ja) | 2014-03-19 | 2020-05-27 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物 |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
| GB201506786D0 (en) * | 2015-04-21 | 2015-06-03 | Ucb Biopharma Sprl | Therapeutic use |
| KR20180058741A (ko) | 2015-09-14 | 2018-06-01 | 인피니티 파마슈티칼스, 인코포레이티드 | 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법 |
| WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
| GB201604970D0 (en) | 2016-03-23 | 2016-05-04 | Syngenta Participations Ag | Improvements in or relating to organic compounds |
| GB201608797D0 (en) * | 2016-05-19 | 2016-07-06 | Ucb Biopharma Sprl | Therapeutic use |
| WO2017214269A1 (en) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| EP3474856B1 (en) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CN108239076B (zh) * | 2016-12-26 | 2021-07-06 | 中国医学科学院药物研究所 | 喹唑啉类化合物及其制备方法、用途和药物组合物 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| GB201708856D0 (en) | 2017-06-02 | 2017-07-19 | Ucb Biopharma Sprl | Seletalisib crystalline forms |
| AU2019262195A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
| AU2019262579A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Salts of an FGFR inhibitor |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| BR112022007163A2 (pt) | 2019-10-14 | 2022-08-23 | Incyte Corp | Heterociclos bicíclicos como inibidores de fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2137186T3 (pl) * | 2007-03-23 | 2016-09-30 | Związki heterocykliczne i ich zastosowania | |
| WO2008118455A1 (en) | 2007-03-23 | 2008-10-02 | Amgen Inc. | δ3- SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE ( PI3K) INHIBITORS |
| EP2132207A2 (en) | 2007-03-23 | 2009-12-16 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2009081105A2 (en) | 2007-12-21 | 2009-07-02 | Ucb Pharma S.A. | Quinoxaline and quinoline derivatives as kinase inhibitors |
| GB0819593D0 (en) | 2008-10-24 | 2008-12-03 | Ucb Pharma Sa | Therapeutic agents |
| WO2011058108A1 (en) * | 2009-11-12 | 2011-05-19 | Ucb Pharma S.A. | Quinoline and quinoxaline derivatives as kinase inhibitors |
| AR082799A1 (es) * | 2010-09-08 | 2013-01-09 | Ucb Pharma Sa | Derivados de quinolina y quinoxalina como inhibidores de quinasa |
-
2011
- 2011-08-30 AR ARP110103154A patent/AR082799A1/es active IP Right Grant
- 2011-09-02 EP EP20110755423 patent/EP2614061B1/en active Active
- 2011-09-02 BR BR112013004750-0A patent/BR112013004750B1/pt active IP Right Grant
- 2011-09-02 DK DK11755423.8T patent/DK2614061T3/en active
- 2011-09-02 ME MEP-2015-120A patent/ME02203B/me unknown
- 2011-09-02 PL PL11755423T patent/PL2614061T3/pl unknown
- 2011-09-02 MY MYPI2013000767A patent/MY162396A/en unknown
- 2011-09-02 NZ NZ607966A patent/NZ607966A/en unknown
- 2011-09-02 US US13/821,294 patent/US9029392B2/en active Active
- 2011-09-02 MA MA35807A patent/MA34600B1/fr unknown
- 2011-09-02 AU AU2011300521A patent/AU2011300521B2/en active Active
- 2011-09-02 EA EA201300317A patent/EA024162B1/ru not_active IP Right Cessation
- 2011-09-02 WO PCT/GB2011/051647 patent/WO2012032334A1/en active Application Filing
- 2011-09-02 JP JP2013527681A patent/JP5820882B2/ja active Active
- 2011-09-02 ES ES11755423.8T patent/ES2544289T3/es active Active
- 2011-09-02 KR KR1020137008975A patent/KR101880280B1/ko active IP Right Grant
- 2011-09-02 MX MX2013002529A patent/MX2013002529A/es active IP Right Grant
- 2011-09-02 PT PT117554238T patent/PT2614061E/pt unknown
- 2011-09-02 CA CA2808959A patent/CA2808959C/en active Active
- 2011-09-02 SI SI201130542T patent/SI2614061T1/sl unknown
- 2011-09-02 CN CN201180049091.2A patent/CN103153996B/zh active Active
- 2011-09-02 RS RS20150538A patent/RS54202B1/en unknown
- 2011-09-02 HU HUE11755423A patent/HUE025223T2/en unknown
- 2011-09-02 SG SG2013012794A patent/SG187924A1/en unknown
- 2011-09-06 TW TW100132061A patent/TWI510489B/zh active
-
2013
- 2013-02-21 IL IL224841A patent/IL224841A/en active IP Right Grant
- 2013-03-01 CL CL2013000603A patent/CL2013000603A1/es unknown
- 2013-03-07 ZA ZA2013/01751A patent/ZA201301751B/en unknown
- 2013-03-21 CO CO13056775A patent/CO6680717A2/es active IP Right Grant
- 2013-07-30 HK HK13108926.7A patent/HK1181754A1/xx unknown
-
2015
- 2015-08-11 SM SM201500195T patent/SMT201500195B/xx unknown
- 2015-08-13 HR HRP20150868TT patent/HRP20150868T1/hr unknown
- 2015-08-18 CY CY20151100718T patent/CY1116734T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| ES2590504T3 (es) | N-ciclilamidas como nematicidas | |
| PE20170677A1 (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret) | |
| PE20161066A1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| EA201100580A1 (ru) | Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20121506A1 (es) | Compuestos triazolopiridinas como inhibidores de c-met | |
| PE20161475A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| EA201001769A1 (ru) | Производные хинолинов и хиноксалинов в качестве ингибиторов протеинтирозинкиназы | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| EA200601364A1 (ru) | Производные хинолина и их применение в качестве ингибиторов микобактерий | |
| CR20140045A (es) | Compuestos de n-tio-antranilamida y sus usos como plaguicidas | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| EA201100763A1 (ru) | Методы получения хинолиновых производных | |
| AR081978A1 (es) | Derivados fusionados de pirimidina para la inhibicion de la actividad quinasa de tirosina | |
| EA201001683A1 (ru) | Производные фенил- или пиридинилзамещенных индазолов | |
| EA201490912A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
| PE20140970A1 (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazol [3,4-d) pirimidin-4-ona y su uso como inhibidores de pde9a | |
| NO20072963L (no) | 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere | |
| NZ703714A (en) | 2-aminopyrazine derivatives as csf-1 r kinase inhibitors | |
| DE602005008953D1 (de) | Substituierte chinolinderivate als inhibitoren von mitotischem kinesin | |
| ES2662444T3 (es) | Derivado de piridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |